[Skip to Content]
[Skip to Content Landing]
December 11, 2002

Risks of Postmenopausal Hormone Replacement

Author Affiliations

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002American Medical Association

JAMA. 2002;288(22):2819. doi:10.1001/jama.288.22.2819

To the Editor: The Women's Health Initiative (WHI) investigators1 stopped the estrogen plus progestin vs placebo arm of their study because they found that women receiving estrogen plus progestin had a significantly higher risk of breast cancer, coronary heart disease (CHD), stroke, and pulmonary embolus (PE). The authors claim, based on these results, that this hormone replacement therapy (HRT) should not be recommended for primary prevention of CHD in women.

First Page Preview View Large
First page PDF preview
First page PDF preview